Drug Profile
INGN 251
Alternative Names: Ad-PTEN; Adenoviral-PTEN; PTEN gene therapyLatest Information Update: 07 Feb 2005
Price :
$50
*
At a glance
- Originator Cancer Research Technology
- Developer Cancer Research Technology; Introgen Therapeutics; Texas Heart Institute
- Class Antineoplastics; Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Brain cancer; Cardiovascular disorders; Colorectal cancer; Malignant melanoma; Urogenital cancer
Most Recent Events
- 07 Feb 2005 Discontinued - Preclinical for Brain cancer in United Kingdom (unspecified route)
- 07 Feb 2005 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 07 Feb 2005 Discontinued - Preclinical for Colorectal cancer in USA (unspecified route)